Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AUS 131

Drug Profile

AUS 131

Alternative Names: AUS-131; S-equol

Latest Information Update: 28 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ausio Pharmaceuticals
  • Developer Ausio Pharmaceuticals; University of Kansas Medical Center; University of Texas Health Science Center at San Antonio
  • Class Antidementias; Antineoplastics; Isoflavones; Small molecules
  • Mechanism of Action Estrogen receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Benign prostatic hyperplasia; Vasomotor symptoms
  • Phase I/II Alzheimer's disease
  • No development reported Osteoporosis; Triple negative breast cancer

Most Recent Events

  • 28 Jun 2022 No recent reports of development identified for phase-0 development in Breast-cancer(First-line therapy) in USA (PO, Tablet)
  • 09 Jun 2020 AUS 131 is still in phase-0 development in Triple negative Breast-cancer(First-line therapy) in USA (PO, Tablet) (NCT02352025)
  • 29 May 2020 Efficacy and adverse events data from a phase 0 trial in Breast cancer presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top